Organovo (NASDAQ:ONVO) Earns Sell Rating from Analysts at StockNews.com

StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO) in a research report sent to investors on Friday. The brokerage issued a sell rating on the medical research company’s stock.

Organovo Stock Performance

Shares of ONVO stock opened at $2.12 on Friday. The firm has a fifty day moving average of $4.70 and a 200-day moving average of $4.94. The stock has a market cap of $3.61 million, a price-to-earnings ratio of -2.49 and a beta of 1.13. Organovo has a 52-week low of $1.96 and a 52-week high of $21.96.

Organovo (NASDAQ:ONVO) last posted its quarterly earnings results on Wednesday, February 19th. The medical research company reported ($2.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.52) by $0.24. The firm had revenue of $0.02 million during the quarter, compared to analyst estimates of $0.05 million. Organovo had a negative net margin of 10,151.64% and a negative return on equity of 346.26%. On average, sell-side analysts predict that Organovo will post -0.77 earnings per share for the current year.

About Organovo

Organovo Holdings, Inc, a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture.